NEX Health Intelligence Ltd.

Based in the UK, NEX Health Intelligence Ltd. delivers innovative solutions for infection control in healthcare, integrating advanced risk intelligence and surveillance into one robust platform for hospitals and healthcare facilities. NEX Health Intelligence Ltd. specializes in infection intelligence, providing solutions tailored for healthcare environments.

Founded in 2022 in Bolton, UK by Dr. Ashleigh Myall and Dr. Chang Ho Yoon the company has successfully completed one funding round. In May 2026, it raised EUR 1 million in pre-seed funding, led by Brighteye Ventures.

The firm does not have any known subsidiaries or parent companies. NEX Health Intelligence offers a comprehensive Infection Intelligence Platform specifically designed for modern hospitals. The platform integrates infection-specific risk intelligence, outbreak investigation, and surveillance automation into a single clinical-grade system. This solution empowers hospitals to detect infection risks earlier, respond with confidence, and ultimately prevent avoidable infections.

By utilizing AI-powered risk intelligence, the platform identifies high-risk patients and optimizes outbreak containment through rapid detection and investigation. NEX's primary clients include hospitals and healthcare facilities operating in diverse geographical markets, including North America, Europe, and select regions in Asia. The end users of this technology primarily consist of infection control teams, microbiology departments, and nursing staff who rely on timely data and insights to enhance patient safety and operational efficiency. NEX Health Intelligence generates revenue through a subscription-based model for its Infection Intelligence Platform.

Clients, typically hospitals, engage in service agreements that provide them access to the platform’s suite of features, including real-time risk monitoring and automated surveillance tools. Transactions are structured as recurring subscriptions, allowing healthcare organizations to budget for predictable costs associated with infection control efforts. Specific pricing plans are tailored to each client based on the size of the facility and the scope of services required, ensuring that hospitals receive the necessary tools to effectively combat infection risks. The platform's flagship services drive consistent engagement and renewals, contributing to NEX's steady revenue stream as healthcare providers increasingly prioritize robust infection prevention solutions.

In May 2026, NEX Health Intelligence Ltd. raised EUR 1 million in funding, which will be utilized to support its expansion within the United Kingdom and internationally, as well as to enhance regulatory and clinical safety standards. The company aims to generate clinical and economic evidence that underscores the effectiveness of its technology. Future growth strategies include launching upcoming products designed to further refine its Infection Intelligence Platform and exploring new geographic markets to enhance its reach by 2027.